ATTAIN-OA PAINOrforglipron for Obesity and Knee Osteoarthritis

This clinical trial is focused on testing a medication called orforglipron to see how effective and safe it is for people who are either obese or overweight and also suffer from knee osteoarthritis, a common cause of knee pain. Osteoarthritis is a condition where the joint cartilage breaks down, leading to pain and stiffness. By studying this medication, researchers aim to potentially provide a new treatment option that could help alleviate knee pain and improve the quality of life for those affected by both obesity and osteoarthritis. Participants in the study will take orforglipron once a day, and the trial will last for about 74 weeks. During this time, participants will be closely monitored to evaluate the effectiveness of the medication in reducing knee pain and its overall safety. The study is designed as a double-blind trial, meaning neither the participants nor the researchers know who is receiving the actual medication or a placebo, which helps ensure unbiased results. The study aims to gather comprehensive data on the potential benefits and any side effects of orforglipron in treating knee osteoarthritis in individuals with obesity or overweight.